About

Our goal is to utilize the complex actions and interactions of the immune system to help researchers better understand the causes, accelerate the diagnosis, and more accurately predict the prognosis of diseases. To that end, Immudex markets prime Dextramer® and dCODE® (DNA-barcoded) MHC multimer technologies that grant researchers and clinicians detailed insights into disease-specific immunity resolved to antigen-specific cell populations and single cells.

Additionally, Immudex is mandated by the CIC and CIMT to coordinate yearly evaluations of T-cell immune monitoring proficiency and drive the generation of high-quality data that advance immunotherapies.